PTK2 and non-small cell lung carcinoma: In advanced pancreatic cancer, mesothelioma, and NSCLC, a clinical trial evaluating the association of FAK (VS6063) and PD-1 (pembrolizumab) inhibitors is ongoing (NCT02758587).